Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
- miCAR Platform Enables Simultaneous Silencing of Multiple Gene Targets
- Allogene to Deploy miCAR and other Technologies to Create the Next Generation of Allogeneic Cell Products
Antion is an early-stage research company with foundational miRNA technology. In preclinical studies, Antion has demonstrated proof-of-concept for multiplex gene silencing in an allogeneic CAR T cell model. These studies demonstrated the ability of miCAR™ technology to silence multiple gene targets in a single step and indicate this technology has broad application within cell and gene engineering. Allogene plans to deploy miCAR™ with other technologies to develop next-generation strategies for immune evasion and other advances in allogeneic CAR T therapy.
“We believe that Antion has one of the few technology options capable of delivering multiplex gene silencing with a high degree of specificity and potency,” said
As part of this agreement, Antion will exclusively collaborate with Allogene on oncology products for a defined period. Allogene will also have exclusive worldwide rights to commercialize products incorporating Antion technology developed during the collaboration. Allogene will provide Antion an upfront cash payment and a preferred equity investment. Allogene will pay Antion developmental and commercial milestones and a single-digit royalty on any product sales. Allogene will also take a seat on Antion’s Board of Directors.
“This collaboration represents an exciting validation of the power and flexibility of our miCAR platform,” said
About Antion Biosciences
For more information please visit: https://antion.ch/
About Allogene Therapeutics
Allogene’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to progress the research collaboration, Antion’s ability to develop a next-generation approach to immune evasion, the ability to develop and manufacture new therapies from Antion technology, and the potential benefits of Antion technology and AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the
AlloCAR T™ is a trademark of
miCAR™ is a trademark of
Antion Biosciences Contact:
+44 (0)20 3709 5700
Allogene Media/Investor Contact:
Chief Communications Officer
Source: Allogene Therapeutics, Inc.